Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Total Non-Current Liabilities: 2010-2025

Historic Total Non-Current Liabilities for Lineage Cell Therapeutics (LCTX) over the last 12 years, with Sep 2025 value amounting to $23.7 million.

  • Lineage Cell Therapeutics' Total Non-Current Liabilities was N/A to $23.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.7 million, marking a year-over-year change of. This contributed to the annual value of $30.0 million for FY2024, which is N/A change from last year.
  • Lineage Cell Therapeutics' Total Non-Current Liabilities amounted to $23.7 million in Q3 2025, which was down 4.88% from $24.9 million recorded in Q2 2025.
  • Over the past 5 years, Lineage Cell Therapeutics' Total Non-Current Liabilities peaked at $83.6 million during Q4 2021, and registered a low of $10.9 million during Q1 2021.
  • For the 3-year period, Lineage Cell Therapeutics' Total Non-Current Liabilities averaged around $31.9 million, with its median value being $29.0 million (2024).
  • Per our database at Business Quant, Lineage Cell Therapeutics' Total Non-Current Liabilities skyrocketed by 575.15% in 2021 and then crashed by 38.14% in 2022.
  • Over the past 5 years, Lineage Cell Therapeutics' Total Non-Current Liabilities (Quarterly) stood at $83.6 million in 2021, then tumbled by 38.14% to $51.7 million in 2022, then dropped by 25.71% to $40.4 million in 2023, then reached $30.0 million in 2024, then reached $23.7 million in 2025.
  • Its Total Non-Current Liabilities stands at $23.7 million for Q3 2025, versus $24.9 million for Q2 2025 and $28.0 million for Q1 2025.